Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) CFO Sells $212,410.29 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 12,651 shares of the stock in a transaction on Friday, September 20th. The shares were sold at an average price of $16.79, for a total transaction of $212,410.29. Following the completion of the transaction, the chief financial officer now directly owns 211,000 shares in the company, valued at $3,542,690. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Oluyemi Okupe also recently made the following trade(s):

• On Tuesday, September 3rd, Oluyemi Okupe sold 11,609 shares of Hims & Hers Health stock. The shares were sold at an average price of $14.60, for a total transaction of $169,491.40.
• On Tuesday, June 25th, Oluyemi Okupe sold 11,546 shares of Hims & Hers Health stock. The stock was sold at an average price of $22.21, for a total value of $256,436.66.

Hims & Hers Health Trading Down 0.1 %

Shares of HIMS opened at $17.26 on Thursday. The firm has a market capitalization of $3.71 billion, a PE ratio of -1,725.50 and a beta of 1.05. The stock’s 50 day moving average is $17.01 and its two-hundred day moving average is $17.13. Hims & Hers Health, Inc. has a twelve month low of $5.65 and a twelve month high of $25.74.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. The firm had revenue of $315.65 million during the quarter, compared to analysts’ expectations of $302.43 million. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. Hims & Hers Health’s revenue was up 51.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.03) earnings per share. On average, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.22 EPS for the current year.

Institutional Trading of Hims & Hers Health

A number of institutional investors have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC increased its holdings in Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after buying an additional 1,603 shares in the last quarter. Quest Partners LLC increased its stake in Hims & Hers Health by 5,944.1% in the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after purchasing an additional 3,507 shares in the last quarter. Van ECK Associates Corp acquired a new position in Hims & Hers Health during the second quarter worth $111,000. Belpointe Asset Management LLC boosted its position in Hims & Hers Health by 10.0% during the fourth quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock worth $118,000 after purchasing an additional 1,205 shares in the last quarter. Finally, Amalgamated Bank grew its holdings in Hims & Hers Health by 55.9% in the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after purchasing an additional 2,354 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on HIMS shares. TD Cowen raised their price target on Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, July 11th. Needham & Company LLC assumed coverage on shares of Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 target price on the stock. Jefferies Financial Group lifted their target price on shares of Hims & Hers Health from $14.00 to $23.00 and gave the company a “hold” rating in a report on Thursday, June 27th. Truist Financial increased their price target on shares of Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday, July 18th. Finally, Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Eight research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $19.86.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.